{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T04:30:56Z","timestamp":1786336256828,"version":"build-2736575974"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the real-world efficacy and safety of golidocitinib in patients with relapsed\/refractory peripheral T-cell lymphoma (R\/R PTCL).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Clinical data of 3 patients with R\/R PTCL treated with golidocitinib at our center between May 2024 and November 2025 were retrospectively analyzed. Baseline features, treatment regimens, responses, and adverse events (AEs) were collected and assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Pathological subtypes included PTCL-not otherwise specified (PTCL-NOS, n=2) and monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL, n=1). Following golidocitinib-based therapy, 2 patients achieved complete response (CR) and 1 partial response (PR), yielding an objective response rate (ORR) of 100%. Median follow-up was 6.2 months (range: 4.2\u20139.1 months); median progression-free survival (PFS) was not reached. Treatment-related AEs were predominantly hematological, mostly grade 1\u20132 and manageable. No treatment-related deaths occurred.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Golidocitinib exhibits promising efficacy and a tolerable safety profile in R\/R PTCL, including rare subtypes, supporting its role as a valuable therapeutic option. Larger cohorts are needed for further validation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1891177","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T04:22:04Z","timestamp":1786335724000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world efficacy and safety of golidocitinib in 3 patients with relapsed\/refractory peripheral T-cell lymphoma"],"prefix":"10.3389","volume":"16","author":[{"given":"Bianhong","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Hematology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanying","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuehan","family":"Mao","sequence":"additional","affiliation":[{"name":"Department of Hematology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiao","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxian","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengshuo","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Hematology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihong","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuehua","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.17226\/1626","article-title":"Clinical practice guidelines for golidocitinib in peripheral T-cell lymphoma (2024 edition)","volume":"33","year":"2024","journal-title":"Leukemia Lymphoma"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2023.0464","article-title":"A retrospective analysis of mature T- and NK-cell lymphomas","volume":"21","author":"Jia","year":"2024","journal-title":"Cancer Biol Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"100126","DOI":"10.2139\/ssrn.3750714","article-title":"Comprehensive analysis of peripheral T-cell and natural killer\/T-cell lymphoma in Asian patients","volume":"10","author":"Yoon","year":"2021","journal-title":"Lancet Reg Health West Pac"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-022-01310-3","article-title":"Management of peripheral T-cell lymphomas and the role of transplant","volume":"24","author":"Foley","year":"2022","journal-title":"Curr Oncol Rep"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.218305","article-title":"Outcome of peripheral T-cell lymphoma patients failing first-line therapy","volume":"103","author":"Bellei","year":"2018","journal-title":"Haematologica"},{"key":"B8","doi-asserted-by":"publisher","first-page":"285","DOI":"10.6004\/jnccn.2022.0015","article-title":"T-cell lymphomas, version 2.2022, NCCN guidelines","volume":"20","author":"Horwitz","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.08.013","article-title":"Phase 1 study of golidocitinib in R\/R PTCL","volume":"34","author":"Song","year":"2023","journal-title":"Ann Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-019-00545-5","article-title":"Targeting the JAK\/STAT pathway in T-cell lymphoproliferative disorders","volume":"14","author":"Shouse","year":"2019","journal-title":"Curr Hematol Malig Rep"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-11-764357","article-title":"Novel insights into the pathogenesis of T-cell lymphomas","volume":"131","author":"Van Arnam","year":"2018","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/s41408-026-01452-8","article-title":"Phase 2 multicenter maintenance study of golidocitinib, a JAK1 selective inhibitor, in patients with peripheral T cell lymphomas after first-line systemic therapy (JACKPOT26)","volume":"16","author":"Wei","year":"2026","journal-title":"Blood Cancer J"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.3390\/cancers13112672","article-title":"JAK-STAT signaling in peripheral T-cell lymphoma: pathogenesis and therapeutic opportunities","volume":"23","author":"Ptasznik","year":"2021","journal-title":"Cancers"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106210","article-title":"The JAK\/STAT pathway and its inhibitors in diseases","volume":"80","author":"Xin","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11111711","article-title":"STAT3 dysregulation in mature T\/NK lymphomas","volume":"11","author":"Seffens","year":"2019","journal-title":"Cancers"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b01392","article-title":"Discovery of AZD4205, a selective JAK1 inhibitor","volume":"63","author":"Su","year":"2020","journal-title":"J Med Chem"},{"key":"B17","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13148-023-01436-6","article-title":"JAK-STAT-mediated chromatin remodeling in NK\/T-cell lymphoma","volume":"15","author":"Chen","year":"2023","journal-title":"Clin Epigenet"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.1016\/j.jid.2021.04.023","article-title":"JAK-STAT inhibition synergizes with romidepsin in cutaneous T-cell lymphoma","volume":"141","author":"Cortes","year":"2021","journal-title":"J Invest Dermatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/cancers18050799","article-title":"JAK inhibitors in the treatment of T-cell lymphomas: current evidence and future directions","volume":"18","author":"Gardenia","year":"2026","journal-title":"Cancers (Basel)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-01-829245","article-title":"STAT3 drives PD-L1 expression in NK\/T-cell lymphoma","volume":"132","author":"Song","year":"2018","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.111717","article-title":"JAK\/STAT plus anti-PD-1\/PD-L1 therapy","volume":"130","author":"Chen","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12943-023-01904-w","article-title":"Therapeutic challenges in peripheral T-cell lymphoma","volume":"23","author":"Luan","year":"2024","journal-title":"Mol Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-024-02089-2","article-title":"Golidocitinib: First Approval. Drugs","volume":"84","author":"Keam","year":"2024"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1891177\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T04:22:05Z","timestamp":1786335725000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1891177\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,10]]},"references-count":23,"alternative-id":["10.3389\/fonc.2026.1891177"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1891177","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,10]]},"article-number":"1891177"}}